145 related articles for article (PubMed ID: 20003822)
1. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus.
Jin O; Zhang H; Gu Z; Zhao S; Xu T; Zhou K; Jiang B; Wang J; Zeng X; Sun L
Cell Mol Immunol; 2009 Dec; 6(6):461-7. PubMed ID: 20003822
[TBL] [Abstract][Full Text] [Related]
2. PDTC attenuate LPS-induced kidney injury in systemic lupus erythematosus-prone MRL/lpr mice.
Zhai JX; Zhang ZX; Feng YJ; Ding SS; Wang XH; Zou LW; Ye DQ
Mol Biol Rep; 2012 Jun; 39(6):6763-71. PubMed ID: 22318546
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
4. Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3.
Moritoki M; Kadowaki T; Niki T; Nakano D; Soma G; Mori H; Kobara H; Masaki T; Kohno M; Hirashima M
PLoS One; 2013; 8(4):e60807. PubMed ID: 23585851
[TBL] [Abstract][Full Text] [Related]
5. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
6. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
Chuan W; Wu-qing W; Zhu-wen Y; Zuo L
Lupus; 2014 Sep; 23(10):994-1005. PubMed ID: 24756437
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.
Ikeda T; Fujii H; Nose M; Kamogawa Y; Shirai T; Shirota Y; Ishii T; Harigae H
Arthritis Res Ther; 2017 Aug; 19(1):187. PubMed ID: 28800777
[TBL] [Abstract][Full Text] [Related]
8. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
Lichtnekert J; Rupanagudi KV; Kulkarni OP; Darisipudi MN; Allam R; Anders HJ
J Immunol; 2011 Sep; 187(6):3413-21. PubMed ID: 21849682
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of BET protein BRD4 delays murine lupus.
Wei S; Sun Y; Sha H
Int Immunopharmacol; 2015 Dec; 29(2):314-319. PubMed ID: 26590112
[TBL] [Abstract][Full Text] [Related]
11. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
12. Aconitine: A potential novel treatment for systemic lupus erythematosus.
Li X; Gu L; Yang L; Zhang D; Shen J
J Pharmacol Sci; 2017 Mar; 133(3):115-121. PubMed ID: 28302448
[TBL] [Abstract][Full Text] [Related]
13. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.
Hou LF; He SJ; Li X; Yang Y; He PL; Zhou Y; Zhu FH; Yang YF; Li Y; Tang W; Zuo JP
Arthritis Rheum; 2011 Aug; 63(8):2445-55. PubMed ID: 21484768
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
[TBL] [Abstract][Full Text] [Related]
15. Proteomics-Based Identification of Potential Therapeutic Targets of Artesunate in a Lupus Nephritis MRL/lpr Mouse Model.
Wen Q; Wang C; Chen D; Luo N; Fan J; Zhou Y; Yu X; Chen W
J Proteome Res; 2024 Apr; 23(4):1150-1162. PubMed ID: 38394376
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
Yang J; Li Q; Yang X; Li M
Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
[TBL] [Abstract][Full Text] [Related]
17. [Effect of CD40 siRNA on inflammatory response of MRL/Lpr mice].
Wang ZH; Zhang W; Zhang YQ; Pang CY; Wang YF
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):771-776. PubMed ID: 27752154
[TBL] [Abstract][Full Text] [Related]
18. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
19. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of systemic lupus erythematosus by Withangulatin A in MRL/lpr mice.
Sun L; Zhou L; Chen M; Zhong R; Liu J
J Cell Biochem; 2011 Sep; 112(9):2376-82. PubMed ID: 21520246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
